The INVO BioScience, Inc. (INVO) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered INVO. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for INVO is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
INVO is a stock in Health Care which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Maxim Group and on the lower end INVO is forecasted to be $ by from Maxim Group.
These are the latest 20 analyst ratings of INVO.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Scott Henry Roth Capital | Neutral | $2 | Downgrade | Apr 13, 2022 |
Maxim Group | Buy | Initiates | Jan 19, 2022 | |
Scott Henry Roth Capital | Buy | $5.25 | Maintains | Aug 18, 2021 |
When did it IPO
N/A
Staff Count
25
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Steven M. Shum
Market Cap
$2.8M
In 2023, INVO generated $3.0M in revenue, which was a increase of 267.38% from the previous year. This can be seen as a signal that INVO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.